Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hiram Ruiz Santiago

MOHS-Micrographic Surgery Bayamon, PR Medical Doctor

NPI 1447249768 CMS profile 945210

1845 Carr 2 Ste 907, Bayamon Medical Plz, Bayamon, PR 00959

Open in the dashboard

General payments

$107,542

286 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$181,866 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Hiram Ruiz Santiago of Bayamon, PR is reported in the CMS Open Payments database as having received $107,542 across 286 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $181,866 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,955 49
2024 General $21,531 50
2023 General $10,219 45
2022 General $11,827 44
2021 General $9,053 39
2020 General $5,271 22
2019 General $24,685 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hiram Ruiz Santiago
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Hiram Ruiz Santiago were reported at $24,955. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Hiram Ruiz Santiago MOHS-Micrographic Surgery median Middle half National median
2019 $24,685 $316 $106–$785 $163
2020 $5,271 $162 $68–$412 $114
2021 $9,053 $243 $87–$654 $132
2022 $11,827 $300 $102–$887 $149
2023 $10,219 $364 $125–$1,010 $160
2024 $21,531 $445 $142–$1,108 $164
2025 $24,955 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $62,495 155 payments
  2. Janssen Biotech, Inc. $29,794 21 payments
  3. E.R. Squibb & Sons, L.L.C. $6,097 18 payments
  4. Genzyme Corporation $3,328 15 payments
  5. Organon LLC $2,400 1 payment
  6. Janssen Pharmaceuticals, Inc $2,279 25 payments
  7. Novartis Pharmaceuticals Corporation $405 22 payments
  8. Eli Lilly Export S.A. Puerto Rico Branch $288 12 payments
  9. PBG Puerto Rico LLC $165 8 payments
  10. Lilly USA, LLC $119 1 payment
  11. Other $172 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $79,981 33 payments
  2. Consulting Fee $15,175 11 payments
  3. Food and Beverage $7,880 232 payments
  4. Honoraria $2,400 1 payment
  5. Travel and Lodging $1,756 4 payments
  6. Education $350 5 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI Immunology $41,767 72 payments
  2. TREMFYA $32,073 46 payments
  3. SKYRIZI Immunology $7,049 21 payments
  4. HUMIRA $5,847 15 payments
  5. RINVOQ $5,138 39 payments
  6. DUPIXENT $3,066 4 payments
  7. VTAMA $2,400 1 payment
  8. STELARA $1,100 1 payment
  9. SOTYKTU $433 11 payments
  10. TALTZ $265 11 payments
  11. Other $965 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,886

Median for Dermatology: 534

Drug cost

$3,182,791

Median for Dermatology: $67,151

Branded share of claims

31.9%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 74 $1,551,618
Dupixent Pen Dupilumab Brand 130 $499,608
Tremfya Guselkumab Brand 32 $442,381
Taltz Autoinjector Ixekizumab Brand 43 $296,131
Stelara Ustekinumab Brand 11 $154,552
Humira(Cf) Pen Adalimumab Brand 21 $143,391
Desonide Generic 212 $25,883
Halobetasol Propionate Generic 177 $11,996
Calcipotriene Generic 43 $9,521
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 176 $8,865

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$56,208

Medicare's payments for the services billed

Medicare patients

155

Average age 78

Services billed

541

72 women, 83 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 63%
Arthritis 41%
Chronic kidney disease 27%
Ischemic heart disease 19%
Cancer 16%
Osteoporosis 15%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $14,471
  • Janssen Pharmaceuticals, Inc $76
$14,547 32 —
SKYRIZI
  • AbbVie, Inc. $6,438
$6,438 74 —
RINVOQ
  • AbbVie, Inc. $287
$287 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $160
$160 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

286 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record